Evaluation of endometrial changes and p53 expression in tamoxifen treated women: comparison of various methods.

OBJECTIVE To compare transvaginal sonography (TVS), sonohysterography (SHG), hysteroscopy and endometrial aspiration (EA) and p53 expression in assessing endometrial abnormalities in women on tamoxifen. METHODS In a cross sectional study of 50 pre- and post-menopausal women receiving tamoxifen for > 2 years, all participants underwent TVS and EA. Those with endometrial thickness > 4 mm on TVS underwent hysteroscopy and SHG. Serum p53 antibody and p53 immunohistochemistry were tested in all women. RESULTS The sensitivity and specificity when compared with histopathology as the reference standard were as follows: TVS 100% and 33.3%, SHG 85.7% and 50%, hysteroscopy 92.8% and 80.8%, serum p53 50% and 83.3%, and p53 immunohistochemistry 57.1% and 61.1%. Prevalence of endometrial abnormalities was not significantly different in asymptomatic and symptomatic women. CONCLUSION Tamoxifen-users require routine testing for endometrial evaluation. TVS followed by hysteroscopy and biopsy is an effective option. p53 expression correlates with histological abnormalities.

[1]  M. Gonen,et al.  Sonohysterography compared with endometrial biopsy for evaluation of the endometrium in tamoxifen-treated women. , 2004, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[2]  P. Aldhous Stem cells: Panacea, or Pandora's box? , 2000, Nature.

[3]  G. Bertelli,et al.  Limited value of sonohysterography for endometrial screening in asymptomatic, postmenopausal patients treated with tamoxifen. , 2000, Gynecologic oncology.

[4]  F. Penault-Llorca,et al.  Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer. , 2000, Gynecologic oncology.

[5]  T. Soussi,et al.  p53 Antibodies in the sera of patients with various types of cancer: a review. , 2000, Cancer research.

[6]  M. Sherman Theories of Endometrial Carcinogenesis: A Multidisciplinary Approach , 2000, Modern Pathology.

[7]  L. Mariani,et al.  Serum evaluation of P53 protein in patients with gynaecological cancer. , 2000, Anticancer research.

[8]  B. Elhelw,et al.  Saline sonohysterography for monitoring asymptomatic postmenopausal breast cancer patients taking tamoxifen , 1999, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[9]  B. Muir,et al.  Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  D. Flex,et al.  Endometrial pathology in postmenopausal tamoxifen treatment: comparison between gynaecologically symptomatic and asymptomatic breast cancer patients. , 1999, Journal of clinical pathology.

[11]  A. V. D. Van Der Zee,et al.  Discrepancy between ultrasonography and hysteroscopy and histology of endometrium in postmenopausal breast cancer patients using tamoxifen. , 1999, Gynecologic oncology.

[12]  I. Cohen,et al.  The role of ultrasound in the detection of endometrial pathologies in asymptomatic postmenopausal breast cancer patients with tamoxifen treatment. , 1998, Obstetrical & gynecological survey.

[13]  T. Bourne,et al.  A randomized trial on the use of ultrasonography or office hysteroscopy for endometrial assessment in postmenopausal patients with breast cancer who were treated with tamoxifen. , 1998, American journal of obstetrics and gynecology.

[14]  T. Kasamatsu,et al.  Random Nuclear p53 Overexpression Pattern In Tamoxifen‐Mediated Endometrial Carcinoma , 1998, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[15]  P. Buytaert Tamoxifen: panacea or Pandora??s box? , 1998 .

[16]  P. Neven,et al.  Longitudinal hysteroscopic follow-up during tamoxifen treatment , 1998, The Lancet.

[17]  K. Hemminki,et al.  Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. , 1996, Cancer research.

[18]  F. Demirkıran,et al.  Ultrasonographic appearance of endometrium in postmenopausal breast cancer patients receiving tamoxifen. , 1996, European journal of obstetrics, gynecology, and reproductive biology.

[19]  A. Figer,et al.  Time-dependent effect of tamoxifen therapy on endometrial pathology in asymptomatic postmenopausal breast cancer patients. , 1996, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[20]  B. Karlan,et al.  HER‐2/neu, p53, and DNA Analyses as Prognosticators for Survival in Endometrial Carcinoma , 1995, Obstetrics and gynecology.

[21]  I. Cohen,et al.  Continuous tamoxifen treatment in asymptomatic, postmenopausal breast cancer patients does not cause aggravation of endometrial pathologies. , 1994, Gynecologic oncology.

[22]  T. Bourne,et al.  Effects of tamoxifen on uterus , 1994, The Lancet.

[23]  A. Kauppila,et al.  Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. , 1993, Obstetrics and gynecology.

[24]  Nils Wilking,et al.  ADJUVANT TAMOXIFEN IN EARLY BREAST CANCER: OCCURRENCE OF NEW PRIMARY CANCERS , 1989, The Lancet.

[25]  I. Zusman,et al.  Serological and immunohistochemical determinations of p53 protein in diagnosis of endometrial cancer: a comparative study. , 1997, European journal of gynaecological oncology.